Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29460270 | 1.00 | ACHE (0.43) | ACHEGRM5SMYD3KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL19996108 | 0.98 | ACHE (0.41) | ACHEGRM5SMYD3KDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL29494753 | 0.84 | KDM4E (0.33) | ACHEGRM5SMYD3KDM4EALDH1A1 | |
| SCHEMBL23003591 | 0.80 | ACHE (0.34) | ACHE | |
| SCHEMBL23029715 | 0.80 | ACHE (0.34) | ACHE | |
| SCHEMBL615681 | 0.77 | KDM4E (0.35) | KDM4EALDH1A1 | |
| SCHEMBL21358497 | 0.76 | SMYD3 (0.31) | SMYD3 | |
| SCHEMBL12441450 | 0.75 | ACHE (0.58) | ACHEGRM5KDM4EALDH1A1 | |
| SCHEMBL12583113 | 0.73 | ACHE (0.56) | ACHE | |
| SCHEMBL19369167 | 0.73 | ACHE (0.56) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11230555-B2 | Bicyclic RORγ modulators | ESCALIER BIOSCIENCES B.V. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230555-B2 | Bicyclic RORγ modulators | ESCALIER BIOSCIENCES B.V. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210053987-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2021-02-25 | — | — | US | disclosed |
| US-20210053987-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2021-02-25 | — | — | US | disclosed |
| EP-3765009-A1 | BICYCLIC ROR-GAMMA MODULATORS | Escalier Biosciences, BV (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019177996-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019177996-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| EP-2444084-A1 | Use of PI3K inibitors for the treatment of obesity | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| EP-2419429-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-22 | — | — | EP | disclosed |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010119264-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010119264-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) | 2010-10-21 | — | — | WO | disclosed |
| US-7754712-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | ACHE 2106/4885GRM5 1817/4885SMYD3 1170/4885 |
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | ACHE 17/4885GRM5 691/4885SMYD3 2398/4885 |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | ACHE 17/4885GRM5 379/4885SMYD3 1776/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | ACHE 4400/4885GRM5 2124/4885SMYD3 1325/4885 |
| US-11230555-B2 | Bicyclic RORγ modulators | RORC, RORA, RORB | ACHE 4574/4885GRM5 352/4885SMYD3 4549/4885 |
| US-20210053987-A1 | BICYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | ACHE 4169/4885GRM5 297/4885SMYD3 4573/4885 |
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | ACHE 17/4885GRM5 691/4885SMYD3 2398/4885 |
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | ACHE 4169/4885GRM5 297/4885SMYD3 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.